After Three-Year Lull, Alcon Cited For Professional Ad Violations
This article was originally published in The Pink Sheet Daily
Executive Summary
DDMAC has sent five letters since 2003 for violations in promotional materials directed at health care professionals.
You may also be interested in...
‘Tis The Season… For An FDA Enforcement Letter To Alcon
The eighth enforcement letter from FDA in a decade cites the company for unjustified claims about its seasonal allergic rhinitis drug, Patanase.
Rebate Card For Alcon’s Pataday Is More Than Meets The Eye, FDA Says
Promotion is not a reminder ad since the ophthalmic’s indication is depicted graphically, a notice of violation letter contends. Citation about advertising and promotional infractions is the second in about a year for Alcon Research.
Allergan Promo For Acular LS Broadens Indications, FDA Warning Letter Says
Journal ad for the ophthalmic misleadingly suggests the drug is indicated for phacoemulsification, according to FDA.